MA-SKYHOOK
4.3.2021 15:02:09 CET | Business Wire | Press release
Skyhook, the leading independent Wi-Fi, Cell and Hybrid location provider, has been chosen by Tive® to enhance the hyper-accurate location of in-transit shipments. Tive helps logistics professionals actively monitor the location and condition of loads with data on location, temperature, shock, light exposure, and humidity. Skyhook's Precision Location solution will replace and supplement existing location sources on specific models of Tive shipment trackers . With Skyhook's location positioning, Tive's customers gain greater visibility into how materials and equipment move throughout their supply chains.
Location tracking helps shippers and logistics service providers (LSP) understand the overall supply chain flow, identify and anticipate disruptions, predict delivery ETAs, and allow for constant improvements through comprehensive analytics and optimization. Tive provides real-time in-transit visibility for eliminating preventable delays and damage and chose Skyhook based on their hybrid location approach, ability to provide location positioning in various environments, and low impact on tracker battery life. Skyhook will be used across the Tive Data Cloud and Open Visibility Network (OVN), assuring that loads are visible even when entering locations where traditional GPS would fail, such as when shipments enter a warehouse.
Skyhook's Precision Location solution, which triangulates cellular, and Wi-Fi signals along with GPS to calculate a tracker's location, extends real-time visibility into a shipment's current location. The integration of Skyhook services delivers real benefits such as improved inventory control, loss and theft prevention by accessing immediate location information, greater operational efficiency, and overall improved visibility.
"Skyhook is thrilled to work with Tive to make it easier for businesses to track and monitor their modern supply chain," said Craig Waggy, CEO, Skyhook. "Our unique hybrid approach is a great fit for asset tracking companies looking to understand how their products are moving across the globe."
"The next generation of in-transit visibility is adding more ways to stream meaningful data in real-time, so logistics professionals can actively manage shipments and avoid delays and damage,” said Lennon Acosta, Sr. Director, software engineering, Tive. "Hyper-accurate location and connectivity is a cornerstone - and Skyhook delivers both. And our Open Visibility Network delivers that data to mutual customers of project44 and FourKites , creating a new industry standard in in-transit visibility.”
Skyhook and Tive look forward to continuing their partnership with future products. To find out more about Skyhook's location solution for asset tracking, visit this page: https://www.skyhook.com/asset-tracking
About Skyhook:
Skyhook is the worldwide independent leader in location technology, operating the world's largest independent location network, consisting of 5.1 billion geolocated Wi-Fi hotspots and 200 million cell towers. Skyhook processes tens of billions of location transactions, serving devices, apps, wearables, brands and advertising platforms with precise and accurate location data and intelligence. Skyhook, through its parent company Skyhook Holding, Inc., operates as a wholly owned subsidiary of Liberty Broadband Corporation. To learn more visit www.skyhook.com .
About Tive
Tive is a leading provider of real-time supply chain visibility insights that help logistics professionals actively manage their in-transit shipments’ location and condition. With Tive, shippers and logistics service providers (LSP) eliminate preventable delays, damage, and shipment failures. Tive’s solution provides data generated by its industry-leading trackers allowing clients to actively optimize their shipments, improve their customers’ experience, and unlock supply chain insights in an actionable real-time manner. For more information, visit www.tive.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210304005102/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
